KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Operating Expenses (2017 - 2025)

Moderna (MRNA) has disclosed Operating Expenses for 9 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 30.61% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 billion through Dec 2025, down 30.12% year-over-year, with the annual reading at $5.0 billion for FY2025, 30.12% down from the prior year.
  • Operating Expenses for Q4 2025 was $1.5 billion at Moderna, up from $1.3 billion in the prior quarter.
  • The five-year high for Operating Expenses was $3.8 billion in Q3 2023, with the low at $671.0 million in Q1 2021.
  • Average Operating Expenses over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2021.
  • The sharpest move saw Operating Expenses skyrocketed 583.6% in 2021, then crashed 49.73% in 2024.
  • Over 5 years, Operating Expenses stood at $1.8 billion in 2021, then skyrocketed by 94.56% to $3.5 billion in 2022, then fell by 19.95% to $2.8 billion in 2023, then fell by 21.14% to $2.2 billion in 2024, then plummeted by 30.61% to $1.5 billion in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.5 billion, $1.3 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.